161 related articles for article (PubMed ID: 38282955)
21. Real-life effectiveness of ustekinumab in inflammatory bowel disease patients with concomitant psoriasis or psoriatic arthritis: An IG-IBD study.
Pugliese D; Daperno M; Fiorino G; Savarino E; Mosso E; Biancone L; Testa A; Sarpi L; Cappello M; Bodini G; Caprioli F; Festa S; Laino G; Maconi G; Mazzuoli S; Mocci G; Sartini A; D'Amore A; Alivernini S; Gremese E; Armuzzi A
Dig Liver Dis; 2019 Jul; 51(7):972-977. PubMed ID: 30992173
[TBL] [Abstract][Full Text] [Related]
22. The Risk of Later Diagnosis of Inflammatory Bowel Disease in Patients With Dermatological Disorders Associated With Inflammatory Bowel Disease.
King D; Chandan JS; Thomas T; Nirantharakumar K; Reulen RC; Adderley NJ; Trudgill N
Inflamm Bowel Dis; 2021 Oct; 27(11):1731-1739. PubMed ID: 34669933
[TBL] [Abstract][Full Text] [Related]
23. The Impact of Inflammatory Bowel Disease in Canada 2018: Extra-intestinal Diseases in IBD.
Bernstein CN; Benchimol EI; Bitton A; Murthy SK; Nguyen GC; Lee K; Cooke-Lauder J; Kaplan GG
J Can Assoc Gastroenterol; 2019 Feb; 2(Suppl 1):S73-S80. PubMed ID: 31294387
[TBL] [Abstract][Full Text] [Related]
24. New onset inflammatory bowel disease in patient treated with secukinumab: Case report and review of literature.
Ali AK; Torosian A; Porter C; Bloomfeld RS; Feldman SR
Dermatol Ther; 2021 Nov; 34(6):e15151. PubMed ID: 34609037
[TBL] [Abstract][Full Text] [Related]
25. Inflammatory Bowel Diseases Affect the Phenotype and Disease Course of Coexisting Immune-Mediated Inflammatory Diseases: A Systematic Review With Meta-Analysis.
Attauabi M; Wewer MD; Bendtsen F; Seidelin JB; Burisch J
Inflamm Bowel Dis; 2022 Nov; 28(11):1756-1765. PubMed ID: 35134921
[TBL] [Abstract][Full Text] [Related]
26. Incidence of Immune-Mediated Inflammatory Diseases Among Patients With Inflammatory Bowel Diseases in Denmark.
Burisch J; Jess T; Egeberg A
Clin Gastroenterol Hepatol; 2019 Dec; 17(13):2704-2712.e3. PubMed ID: 30936024
[TBL] [Abstract][Full Text] [Related]
27. Incidence rates of inflammatory bowel disease in patients with psoriasis, psoriatic arthritis and ankylosing spondylitis treated with secukinumab: a retrospective analysis of pooled data from 21 clinical trials.
Schreiber S; Colombel JF; Feagan BG; Reich K; Deodhar AA; McInnes IB; Porter B; Das Gupta A; Pricop L; Fox T
Ann Rheum Dis; 2019 Apr; 78(4):473-479. PubMed ID: 30674475
[TBL] [Abstract][Full Text] [Related]
28. Psoriasis concurrent with inflammatory bowel disease.
Park HS; Koh SJ; Park GY; Lee DH; Yoon HS; Youn JI; Cho S
J Eur Acad Dermatol Venereol; 2014 Nov; 28(11):1436-41. PubMed ID: 25493315
[TBL] [Abstract][Full Text] [Related]
29. [Two-year incidence of new immune-mediated inflammatory diseases in patients with inflammatory bowel disease: A study in the AQUILES cohort].
Marín-Jiménez I; Gisbert JP; Pérez-Calle JL; García-Sánchez V; Tabernero S; García-Vicuña R; Romero C; Juliá B; Vanaclocha F; Cea-Calvo L;
Gastroenterol Hepatol; 2015 Dec; 38(10):569-74. PubMed ID: 25983283
[TBL] [Abstract][Full Text] [Related]
30. Children and Adolescents Diagnosed With Inflammatory Bowel Disease Are at Increased Risk of Developing Diseases With a Possible Autoimmune Pathogenesis.
Jølving LR; Zegers FD; Lund K; Wod M; Nielsen J; Qvist N; Nielsen RG; Nørgård BM
Inflamm Bowel Dis; 2024 Mar; ():. PubMed ID: 38507606
[TBL] [Abstract][Full Text] [Related]
31. Patients with inflammatory bowel disease have increased risk of autoimmune and inflammatory diseases.
Halling ML; Kjeldsen J; Knudsen T; Nielsen J; Hansen LK
World J Gastroenterol; 2017 Sep; 23(33):6137-6146. PubMed ID: 28970729
[TBL] [Abstract][Full Text] [Related]
32. The Gut Microbiome in Psoriasis and Crohn's Disease: Is Its Perturbation a Common Denominator for Their Pathogenesis?
De Francesco MA; Caruso A
Vaccines (Basel); 2022 Feb; 10(2):. PubMed ID: 35214702
[TBL] [Abstract][Full Text] [Related]
33. Occurrence of inflammatory bowel disease in patients with chronic inflammatory skin diseases: a cohort study: Classification: Epidemiology.
Schneeweiss MC; Kirchgesner J; Wyss R; Jin Y; York C; Merola JF; Mostaghimi A; Silverberg JI; Schneeweiss S; Glynn RJ
Br J Dermatol; 2022 Nov; 187(5):692-703. PubMed ID: 35718888
[TBL] [Abstract][Full Text] [Related]
34. Clinical characteristics of patients with spondyloarthritis and inflammatory bowel disease versus inflammatory bowel disease-related arthritis.
Ono K; Kishimoto M; Deshpande GA; Fukui S; Kawaai S; Sawada H; Matsuura M; Rodriguez VR; Proft F; Tada K; Tamura N; Taniguchi Y; Hirata A; Kameda H; Tsuji S; Kaneko Y; Dobashi H; Okano T; Haji Y; Morita A; Okada M; Komagata Y; Medina CL; Molto A; Dougados M; Hisamatsu T; Tomita T; Kaname S
Rheumatol Int; 2022 Oct; 42(10):1751-1766. PubMed ID: 35532790
[TBL] [Abstract][Full Text] [Related]
35. Characterization and prevalence of spondyloarthritis and peripheral arthritis among patients with inflammatory bowel disease.
Malaty HM; Lo GH; Hou JK
Clin Exp Gastroenterol; 2017; 10():259-263. PubMed ID: 29026327
[TBL] [Abstract][Full Text] [Related]
36. Impact of a Patient Support Program on Patient Adherence to Adalimumab and Direct Medical Costs in Crohn's Disease, Ulcerative Colitis, Rheumatoid Arthritis, Psoriasis, Psoriatic Arthritis, and Ankylosing Spondylitis.
Rubin DT; Mittal M; Davis M; Johnson S; Chao J; Skup M
J Manag Care Spec Pharm; 2017 Aug; 23(8):859-867. PubMed ID: 28737994
[TBL] [Abstract][Full Text] [Related]
37. Healthcare resource utilization and costs associated with inflammatory bowel disease among patients with chronic inflammatory diseases: a retrospective cohort study.
Hudesman DP; Chakravarty SD; Emond B; Ellis LA; Lefebvre P; Sadik K; Scher JU
BMC Rheumatol; 2020; 4():16. PubMed ID: 32266326
[TBL] [Abstract][Full Text] [Related]
38. Low Incidence of Inflammatory Bowel Disease Adverse Events in Adalimumab Clinical Trials Across Nine Different Diseases.
Elewaut D; Braun J; Anderson JK; Arikan D; Chen S; Hojnik M; De Craemer AS; Curtis JR
Arthritis Care Res (Hoboken); 2021 Feb; 73(2):289-295. PubMed ID: 32100944
[TBL] [Abstract][Full Text] [Related]
39. Real-world incidence of inflammatory bowel disease among patients with other chronic inflammatory diseases treated with interleukin-17a or phosphodiesterase 4 inhibitors.
Emond B; Ellis LA; Chakravarty SD; Ladouceur M; Lefebvre P
Curr Med Res Opin; 2019 Oct; 35(10):1751-1759. PubMed ID: 31106607
[No Abstract] [Full Text] [Related]
40. Association between autism spectrum disorder and inflammatory bowel disease: A systematic review and meta-analysis.
Kim JY; Choi MJ; Ha S; Hwang J; Koyanagi A; Dragioti E; Radua J; Smith L; Jacob L; Salazar de Pablo G; Lee SW; Yon DK; Thompson T; Cortese S; Lollo G; Liang CS; Chu CS; Fusar-Poli P; Cheon KA; Shin JI; Solmi M
Autism Res; 2022 Feb; 15(2):340-352. PubMed ID: 34939353
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
